about
Adverse events and retention of donors of double red cell units by apheresisHuman platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization.Physiology of iron metabolismAssociations of HLA-A, -B and -DRB1 types with oral diseases in Swiss adults.High-throughput Kell, Kidd, and Duffy matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry-based blood group genotyping of 4000 donors shows close to full concordance with serotyping and detects new alleles.MNSs genotyping by MALDI-TOF MS shows high concordance with serology, allows gene copy number testing and reveals new St(a) alleles.Too Many Blood Donors - Response Bias in the Swiss Health Survey 2012Iron and transfusion medicine.Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists?Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I.Human Microtumors Generated in 3D: Novel Tools for Integrated In Situ Studies of Cancer Immunotherapies.Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.Blood donor to inactive donor transition in the Basel region between 1996 and 2011: a retrospective cohort study.Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study.Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearanceDouble allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies.In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.Vox Sanguinis International Forum on platelet cryopreservation: Summary.Vox Sanguinis International Forum on platelet cryopreservation.Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.Impact of donor ABH-secretor status in ABO-mismatched living donor kidney transplantation.International Forum regarding practices related to donor haemoglobin and iron.Associations of oral fluid MMP-8 with periodontitis in Swiss adult subjects.Numerical impairment of nestin(+) bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML.Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.Iron deficiency and thrombocytosis.Prohormones in the Early Diagnosis of Cardiac Syncope.Effect of Acute Coronary Syndrome Probability on Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin.Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin.Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation.Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention.Role of donor and recipient sex in platelet transfusion.Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.Switching iron-deficient whole blood donors to plateletpheresis.Dkk3 levels in patients with myeloproliferative neoplasms.Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summaryGene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel AgentsHuman pregnancy and generation of anti-angiotensin receptor and anti-perlecan antibodies
P50
Q33167138-4D520243-FE27-4A9E-82A9-E80B3D3014B7Q33440153-2EE1F1A3-6C69-4E27-BBC6-C47EED5EDA22Q33863389-1E625DF5-672A-4824-A065-6B62A929BBBEQ33968450-E05E0718-9070-4C11-8DE0-C1B20B1E20D9Q35171614-A0CF784E-5F5C-4805-A446-51DD4B829789Q35987845-16E62D17-9FA2-4777-9A60-5B94A97AAC1AQ37508120-FABECC91-6100-447A-B2BD-70A26D862700Q38154729-007355FE-1E48-42DC-93C3-C7A35173E998Q38190914-21DEC032-1E87-4AB4-9E08-52134BAFE953Q38210816-EE681243-C617-49A8-9713-679218FD4C39Q38379588-D2A18AA2-908C-4B95-8C98-8F1333C50FC3Q38782039-C0C877DA-3D37-42CB-8ADA-C57AE7D462FEQ39726212-359CE4DF-8E48-445E-954E-C8F3062BE6A1Q40274545-8B17AA36-BD00-46CB-807F-F73CD487AD5BQ40348688-2B9E9908-5F3E-4BD2-8174-0AC34DEECB6CQ42368316-89DB4B1E-2687-420A-9435-F90C8B8FE0BAQ44209876-F68AE6EF-4895-43A5-9ABB-37764B91A919Q47129210-2AFE83CB-FE1B-4CFC-9FCB-53176BD1E6DEQ47565277-F05A6F24-CFAE-4A69-B3B3-B5250B8D2BA6Q47565285-AB5DAAE8-940E-4FEC-BCD3-A8E3F9CFE5FDQ47708886-9D4D24A0-3C40-4475-9369-FA1AAB6D4C84Q47747221-2B8FC196-6BCB-4B11-94F9-57DAE38B0573Q48093275-486FABCA-6D24-4117-A9E0-1F3EBE11F640Q48098251-C206383D-C5BE-4EB6-9E60-B02D5D40DEBAQ48142819-70811961-2D65-4137-B474-526C9F2F7CACQ48187625-6AC290E2-714C-4DF9-B7E9-80EC73B6B64CQ48210112-ED055812-0035-4040-A1BA-1931CA4FF460Q49707707-B2DC24DA-3E62-460A-ABCF-17C236710B3FQ49990287-4AF2DFA1-E701-4712-B6A9-11B3E33D5E0EQ50217429-0D883EE4-3EA2-41AC-9F2F-BA7BBB8C492AQ50438390-97394888-46FC-4BFC-B614-DD382AA50A6BQ50466984-29BAD631-3668-4356-850A-D0A3CEDB9D75Q50489643-94971006-132C-4C04-8F43-C13DA9ABB4DAQ50494399-6877B672-FC14-4E7A-89BA-2C776F683657Q50501531-48213E7E-BE43-480A-9329-EEE7C9634215Q50515460-19A4258D-AE41-4E7D-B5E1-D21FC35123E1Q54392254-9367C689-610E-48F0-887F-83BAA5DE14C1Q59442837-104C8B0F-64F8-407A-AE97-E77EABBD86FEQ62029357-BA13EFE0-9FE1-4B71-9FFE-54C45D9C087DQ87505035-8CED9F6D-9D73-4A65-ABCA-04398C0E9D20
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andreas Buser
@ast
Andreas Buser
@en
Andreas Buser
@es
Andreas Buser
@nl
type
label
Andreas Buser
@ast
Andreas Buser
@en
Andreas Buser
@es
Andreas Buser
@nl
prefLabel
Andreas Buser
@ast
Andreas Buser
@en
Andreas Buser
@es
Andreas Buser
@nl
P108
P106
P1153
6602475202
P31
P496
0000-0002-7942-6746